2019 American Transplant Congress » Concurrent Session: Kidney Chronic Antibody Mediated Rejection

Date: Monday, June 3, 2019

Time: 4:30pm-6:00pm

Location: Ballroom B

Session Type: Concurrent Session

Meeting: 2019 American Transplant Congress

4:30pm-4:42pm: Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation

S. C. Jordan¹, N. Ammerman¹, M. Toyoda², E. Huang¹, C. C. Nast³, A. Peng¹, S. Sethi¹, R. Najjar¹, I. Kim¹, K. Lim¹, J. Choi¹, A. Vo¹

4:42pm-4:54pm: Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR)

B. Shin, S. Ge, A. Petrosyan, N. F. Ammerman, A. A. Vo, S. C. Jordan, M. Toyoda

4:54pm-5:06pm: Using Ensembles of Machine Learning Classifiers to Maximize the Accuracy and Stability of Molecular Biopsy Interpretation

J. Reeve¹, K. S. Madill-Thomsen², P. F. Halloran and the INTERCOMEX Study Group³

5:06pm-5:18pm: Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection

D. Kumar¹, M. Raynaud², P. Halloran³, A. Loupy², J. Chang³, J. Reeve³, I. Yakubu¹, S. Bobba¹, L. Kamal¹, M. Levy¹, C. Bhati¹, P. Kimball¹, A. King¹, G. Gupta¹

5:18pm-5:30pm: Comparing Antibody-Mediated Rejection with or without Detectable DSA: Similar Pathology and Similar Poor Prognosis

G. Einecke¹, J. Reeve², P. F. Halloran³

5:30pm-5:42pm: Long Term Outcomes Using Tocilizumab For The Treatment Of Chronic Antibody Mediated Rejection

J. Choi¹, E. Huang¹, O. Aubert², A. Vo¹, A. Peng¹, R. Najjar¹, S. Sethi¹, N. Ammerman¹, K. Lim¹, D. Puliyanda¹, A. Loupy², S. Jordan¹

« View all sessions from the 2019 American Transplant Congress